PLOD2 Promotes Cutaneous Squamous Cell Carcinoma Progression in Association With STAT3‐Related ERK and AKT Pathways
Molecular Carcinogenesis · 2026-05 · 65 (5) · 615-629
DOI: 10.1002/mc.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 01.03.2026. Verfasst von Ningyi Xian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Cutaneous Squamous Cell Carcinoma, Proto-Oncogene Proteins c-akt, Skin Neoplasms. Die Arbeit nennt 62 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Institutional Foundation of the 503 First Affiliated Hospital of Xi'an Jiaotong University.
Abstract (Originalsprache)
Cutaneous squamous cell carcinoma (cSCC) is a malignant skin cancer which is derived from epidermal keratinocytes, and long‐term exposure to ultraviolet rays is its main risk factor. Procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 2 (PLOD2) is a crucial gene for the formation and stability of collagen intermolecular cross‐links, being vital in the development of cancer. Nevertheless, the interaction between cSCC and PLOD2 has not been elucidated. Here, we found PLOD2 upregulated in human cSCC. Its knockdown in cSCC cells suppressed proliferation, migration, invasion, and angiogenesis while inducing apoptosis and cell cycle arrest; overexpression promoted these malignant phenotypes. In mouse xenografts, PLOD2 knockdown inhibited tumor growth and collagen deposition. Furthermore, in a DMBA/TPA‐induced carcinogenesis model, topical PLOD2 inhibition by minoxidil suppressed tumor development as well. Mechanistically, our studies revealed that PLOD2 acts as a key downstream effector of STAT3 to activate ERK and AKT signaling evidenced by rescue experiments. As a result, our study not only establishes the STAT3/PLOD2/ERK‐AKT axis as a key driver of cSCC but also identifies the clinically approved drug minoxidil as a potent PLOD2 inhibitor, demonstrating immediate promise as a repurposed therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Gastroenterology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Dermatology and Aesthetic Medicine, Xi'an, Shaanxi, China.
- Biomedical Experimental Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
ORCID-Profile: Ningyi Xian, Bingqing Wang
Förderung
- the National Natural Science Foundation of China
- Institutional Foundation of the 503 First Affiliated Hospital of Xi'an Jiaotong University
Zitieren
APA
Xian, N., Wang, Z., Wang, B., Wang, X., & Zheng, Y. (2026). PLOD2 Promotes Cutaneous Squamous Cell Carcinoma Progression in Association With STAT3‐Related ERK and AKT Pathways. Molecular Carcinogenesis, 65(5), 615-629. https://doi.org/10.1002/mc.70102
Vancouver
Xian N, Wang Z, Wang B, Wang X, Zheng Y. PLOD2 Promotes Cutaneous Squamous Cell Carcinoma Progression in Association With STAT3‐Related ERK and AKT Pathways. Molecular Carcinogenesis. 2026;65(5):615-629. doi:10.1002/mc.70102
BibTeX
@article{Xian2026,
author = {Xian, Ningyi and Wang, Ziwei and Wang, Bingqing and Wang, Xiaofei and Zheng, Yan},
title = {PLOD2 Promotes Cutaneous Squamous Cell Carcinoma Progression in Association With STAT3‐Related ERK and AKT Pathways},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {5},
pages = {615--629},
doi = {10.1002/mc.70102}
}
EUVIMED